RT Journal Article
SR Electronic
T1 EPIDEMIOLOGICAL CHARACTERISTICS AND SEVERITY OF OMICRON VARIANT CASES IN THE APHP CRITICAL CARE UNITS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.25.22269839
DO 10.1101/2022.01.25.22269839
A1 Vieillard-Baron, Antoine
A1 Flicoteaux, Rémi
A1 Salmona, Maud
A1 Annane, Djillali
A1 Ayed, Soufia
A1 Azoulay, Elie
A1 Bellaiche, Raphael
A1 Beloucif, Sadek
A1 Berti, Enora
A1 Bertier, Astrid
A1 Besset, Sébastien
A1 Bret, Marlène
A1 Cariou, Alain
A1 Carpentier, Christophe
A1 Chaouch, Oussama
A1 Chariot, Appoline
A1 Charron, Cyril
A1 Charpentier, Julien
A1 Cheurfa, Cherifa
A1 Cholley, Bernard
A1 Clerc, Sébastien
A1 Combes, Alain
A1 Chousterman, Benjamin
A1 Cohen, Yves
A1 Constantin, Jean-Michel
A1 Damoisel, Charles
A1 Darmon, Michael
A1 Degos, Vincent
A1 D’Ableiges, Bertrand De Maupeou
A1 Demeret, Sophie
A1 Montmollin, Etienne De
A1 Demoule, Alexandre
A1 Depret, Francois
A1 Diehl, Jean-Luc
A1 Djibré, Michel
A1 Do, Chung-Hi
A1 Dudoignon, Emmanuel
A1 Duranteau, Jacques
A1 Fartoukh, Muriel
A1 Fieux, Fabienne
A1 Gayat, Etienne
A1 Gennequin, Mael
A1 Guidet, Bertrand
A1 Gutton, Christophe
A1 Hamada, Sophie
A1 Heming, Nicholas
A1 Jouffroy, Romain
A1 Keita-Meyer, Hawa
A1 Langeron, Olivier
A1 Lortat-Jacob, Brice
A1 Marey, Jonathan
A1 Mebazaa, Alexandre
A1 Megarbane, Bruno
A1 Mekontso-Dessap, Armand
A1 Mira, Jean-Paul
A1 Molle, Julie
A1 Mongardon, Nicolas
A1 Montravers, Philippe
A1 Morelot-Panzini, Capucine
A1 Nemlaghi, Safaa
A1 Nguyen, Bao-long
A1 Parrot, Antoine
A1 Pasqualotto, Romain
A1 Peron, Nicolas
A1 Picard, Lucile
A1 de Chambrun, Marc Pineton
A1 Planquette, Benjamin
A1 Plaud, Benoit
A1 Pons, Stéphanie
A1 Quesnel, Christophe
A1 Raphalen, Jean-Herlé
A1 Razazi, Keyvan
A1 Ricard, Jean-Damien
A1 Roche, Anne
A1 Rohaut, Benjamin
A1 Roux, Damien
A1 Savale, Laurent
A1 Sobotka, Jennifer
A1 Teboul, Jean-Louis
A1 Timsit, Jean-François
A1 Voiriot, Guillaume
A1 Weiss, Emmanuel
A1 Wildenberg, Lucille
A1 Zogheib, Elie
A1 Riou, Bruno
A1 Batteux, Frédéric
YR 2022
UL http://medrxiv.org/content/early/2022/01/28/2022.01.25.22269839.abstract
AB Importance Information about the severity of Omicron is scarce.Objective To report the respective risk of ICU admission in patients hospitalized with Delta and Omicron variants and to compare the characteristics and disease severity of critically ill patients infected with both variants according to vaccination status.Design Analysis from the APHP database, called Reality, prospectively recording the following information in consecutive patients admitted in the ICU for COVID-19: age, sex, immunosuppression, vaccination, pneumonia, need for invasive mechanical ventilation, time between symptom onset and ICU admission, and in-ICU mortality. Retrospective analysis on an administrative database, “Système d’Information pour le Suivi des Victimes” (SI-VIC), which lists hospitalized COVID-19 patients.Setting 39 hospitals in the Paris area from APHP group.Participants Patients hospitalized from December 1, 2021 to January 18, 2022 for COVID-19.Main outcomes and measures Risk of ICU admission was evaluated in 3761 patients and Omicron cases were compared to Delta cases in the ICU in 888 consecutive patients.Results On January 18, 45% of patients in the ICU and 63.8% of patients in conventional hospital units were infected with the Omicron variant (p < 0.001). The risk of ICU admission with Omicron was reduced by 64% than with Delta (9.3% versus 25.8% of cases, respectively, p < 0.001). In critically ill patients, 400 had the Delta variant, 229 the Omicron variant, 98 had an uninformative variant screening test and 161 did not have information on variant screening test. 747 patients (84.1%) were admitted for pneumonia. Compared to patients infected with Delta, Omicron patients were more vaccinated (p<0.001), even with 3 doses, more immunocompromised (p<0.001), less admitted for pneumonia (p<0.001), especially when vaccinated (62.1% in vaccinated versus 80.7% in unvaccinated, p<0.001), and less invasively ventilated (p=0.02). Similar results were found in the subgroup of pneumonia but Omicron cases were older. Unadjusted in-ICU mortality did not differ between Omicron and Delta cases, neither in the overall population (20.0% versus 27.9%, p = 0.08), nor in patients with pneumonia (31.6% versus 29.7%, respectively) where adjusted in-ICU mortality did not differ according to the variant (HR 1.43 95%CI [0.89;2.29], p=0.14).Conclusion and relevance Compared to the Delta variant, the Omicron variant is less likely to result in ICU admission and less likely to be associated with pneumonia. However, when patients with the Omicron variant are admitted for pneumonia, the severity seems similar to that of patients with the Delta variant, with more immunocompromised and vaccinated patients and no difference in adjusted in-ICU mortality. Further studies are needed to confirm our results.Competing Interest StatementDr. Vieillard-Baron declares a research grant from Air Liquide. Dr. Mebazaa reports personal fees from Orion, Servier, Otsuka, Philips, Sanofi, Adrenomed, Epygon and Fire 1 and grants and personal fees from 4TEEN4, Abbott, Roche and Sphyngotec. Dr. Gayat declares personal fees from Baxter and Edwards and research grants from Radiometer and Philips. Dr. Chousterman declares being a member of an advisory board for Roche diagnostic and has received speaker fees from Baxter. Dr. Demoule reports grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees and non-financial support from Fisher & Paykel, grants from the French Ministry of Health, personal fees from Getinge, grants, personal fees and non-financial support from Respinor, grants, personal fees and non-financial support from Lungpacer, personal fees from Lowenstein, and personal fees from Gilead. Dr. Teboul declares being a member of the medical advisory board of Getinge and personal speaker fees from Lilly. Dr. Cariou declares speaker fees from Bard. Bernard Cholley has received honoraria (participation in advisory boards) or lecturing fees from Orion Pharma, Edwards Life Sciences, Amomed, and Nordic pharma. Elie Azoulay has received speaker fees and research grants from Sanofi, Alexion and Pfizer. Sebastien Clerc has received financial support (registration at an international meeting) from Oxyvie. Nicolas Mongardon declares being member of an advisory board of Amomed. The other authors do not declare any conflicts of interest. Funding StatementThis study was funded by Assistance Publique des Hopitaux de ParisAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics and scientific committees of the APHP group (CSE-21-32).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.